Shilpa Medicare is scaling formulations, biologics, peptides and CDMO alongside its core API business, with Q1FY27 revenue and profit reaching record levels. After a 238% gain in 2026, the focus is shifting to whether its pipeline and new capacity can sustain earnings growth.
Shilpa Medicare is scaling formulations, biologics, peptides and CDMO alongside its core API business, with Q1FY27 revenue and profit reaching record levels. After a 238% gain in 2026, the focus is shifting to whether its pipeline and new capacity can sustain earnings growth.
<iframe src="https://hindustansphere.com/embed/cluster/135cb33c1385f246b7e506e23ead5136d7e420a7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Shilpa Medicare's 238% Rally Faces An Earnings Test"></iframe>
